AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.
AstraZeneca's anti-CTLA4 antibody tremelimumab is moving closer to what once looked like an extremely unlikely regulatory approval, after a string of negative trial results.
After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.
After two FDA rejections for non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA), Intercept Pharma has agreed to be taken over by Italian drugmaker Alfasig
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho